Dashboard
1
High Debt Company with a Debt to Equity ratio (avg) at times
- Poor long term growth as Net Sales has grown by an annual rate of 5.97% and Operating profit at -0.93% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
- The company has been able to generate a Return on Equity (avg) of 2.68% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Net Sales has grown by an annual rate of 5.97% and Operating profit at -0.93% over the last 5 years
3
Negative results in Mar 25
4
With ROE of 4.78%, it has a very expensive valuation with a 2.30 Price to Book Value
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
CNY 3,746 Million (Small Cap)
48.00
NA
0.00%
0.30
4.78%
2.30
Revenue and Profits:
Net Sales:
613 Million
(Quarterly Results - Jun 2025)
Net Profit:
26 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-0.38%
0%
-0.38%
6 Months
-1.33%
0%
-1.33%
1 Year
-3.35%
0%
-3.35%
2 Years
-17.75%
0%
-17.75%
3 Years
-25.22%
0%
-25.22%
4 Years
-25.32%
0%
-25.32%
5 Years
-34.14%
0%
-34.14%
Beijing Centergate Technologies (Holding) Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
5.97%
EBIT Growth (5y)
-0.93%
EBIT to Interest (avg)
1.64
Debt to EBITDA (avg)
2.15
Net Debt to Equity (avg)
0.24
Sales to Capital Employed (avg)
1.07
Tax Ratio
33.74%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
4.64%
ROE (avg)
2.68%
Valuation key factors
Factor
Value
P/E Ratio
48
Industry P/E
Price to Book Value
2.30
EV to EBIT
27.77
EV to EBITDA
10.83
EV to Capital Employed
2.00
EV to Sales
1.72
PEG Ratio
13.14
Dividend Yield
NA
ROCE (Latest)
7.21%
ROE (Latest)
4.78%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
613.40
608.10
0.87%
Operating Profit (PBDIT) excl Other Income
91.30
73.20
24.73%
Interest
12.90
11.10
16.22%
Exceptional Items
0.00
0.00
Consolidate Net Profit
26.20
18.60
40.86%
Operating Profit Margin (Excl OI)
85.00%
56.00%
2.90%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 0.87% vs 2.53% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 40.86% vs 57.63% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2,497.60
2,244.10
11.30%
Operating Profit (PBDIT) excl Other Income
394.60
350.10
12.71%
Interest
57.40
61.80
-7.12%
Exceptional Items
8.80
-1.90
563.16%
Consolidate Net Profit
76.40
64.90
17.72%
Operating Profit Margin (Excl OI)
59.50%
58.00%
0.15%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 11.30% vs 10.72% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 17.72% vs 342.16% in Dec 2023
About Beijing Centergate Technologies (Holding) Co., Ltd. 
Beijing Centergate Technologies (Holding) Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






